

REFERENCE

- ดำรงศักดิ์ ฟ้าง่อง.2546. หลักเภสัชจลนศาสตร์ของยารับประทาน สงขลา : ภาควิชาเทคโนโลยีเภสัชกรรม คณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์.
(Farongsank, 2003)
- Abraham, M.A., Thomas, P.P., John, G.T., *et al.* 2003.Efficacy and safety of low-dose ketoconazole (50mg) to reduce the cost of cyclosporin in renal allograft recipients. *Transplantation Proceedings.* 35: 215-216.
- Anon.1992. Drug for treatment of fungal infections. *Med.Lett.Drugs Ther.* 34: 14-16.
- Anon.1993. Report of dangerous cardiac arrhythmias prompt new contra-indications for the drug Hismanal. *FDA Med. Bull.* 23(1): 2-3.
- Annas, A., Carlström, K., Alv'an, G. and AL-Shurbaji, A. 2003. The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment. *Br.J.Clin.Pharmacol.*56: 334-336.
- Backman, J.T., Kivisto, K.T., Olkkola, K.T *et al.*1998. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. *Eur.J.Clin.Pharmacol.*54: 53-58.
- Baker, R.L. and Para, M.F.1984. Successful use of ketoconazole for invasive cutaneous *Trichophyton rubrum* infection. *Arch. Intern. Med.*144: 615-617.

- Back, D.J., Stevenson, P., Tija, JF. 1989. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamine, ethinyloestradiol Cyclosporin and ethoxycoumarin by human liver microsomes in vitro. *British Journal of Clinical Pharmacology*. 28 : 166-170.
- Baldwin, S.J., Bloomer, J.C., Smith, G.i., Ayrton, A.D. and Clarke S.E. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. *Xenobiotica*.25: 261-270.
- Balbi, C., D'Ajello, M. and Balbi, G.C.1986. Treatment with ketoconazole in diabetic Patients with vaginal candidiasis. *Drugs Exp. Clin.Res*.12: 413-414.
- Benet, L.Z., Kroetz, D.L. and Sheiner, L.B. 1996. Biotransformation of drugs, in Hardman JG, Limbird LL, Molinoff PB, et al (eds). *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. (9th ed.), pp. 3-28. New York, McGraw-Hill.
- Benet, L.Z., Izumi, T., Zhang, Y., et al.1999. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. *Journal of Controlled release*. 62 (1-2): 25-31.
- Bennett, J.E. 1996. Antifungal agents. In: *Goodman and Gilman's the pharmacological Basis of Therapeutics*. 9th ed, Hardman et al. eds, New York, Pergamon Press, pp.1175-1190.
- Brass, C., Galgiani, J.N., Blaschke, T.F., et al.1982. Disposition of ketoconazole, an oral antifungal, in humans. *Antimicrob Agents*

*Chemother.*21: 151-158.

Brawn, M.W., Maldonado, A.L., Meredith, C.G., *et al.* 1985. Effect of ketoconazole on hepatic oxidative drug metabolism. *Clin.Pharmacol. Ther.*37: 290-297.

Bindschedler, M., Lefevre, G., Ezzet, F., *et al.* 2000. Cardiac effect of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. *Eur.J.Clin.Pharmacol.*56:375-381.

Cleary, JD., Taylor, JW. and Chapman, SW. 1992. Itraconazole in antifungal therapy. *The Annals of Pharmacotherapy.* 26: 502-11.

Carlson, J.A., Mann, H.J. and Canafax, D.M.1983. Effect of pH on disintegration and dissolution of ketoconazole tablets. *Am. J. Hosp. Pharm.* 40: 1334-1336.

Crevoisier, C., Handschin, J., Barre, J., Roumenov, D., Kleinbloesem, C. 1997. Food increases the bioavailability of mefloquine. *Eur J Clin Pharmacol.* 53:135-139.

Como, J.A. and Dismukes, W.E. 1994. Oral azole drugs as systemic antifungal therapy. *New Eng.J.Med.*330:263-272.

Chamber, H.F. 2001. Antimicrobial Agents. *Goodman & Gillman's The pharmacological Basis of Therapeutics* (10th ed.) pp.1301-1304. New York: McGraw-Hill.

- Choo, E.F., Leake, B., Wandel, C., *et al.* 2000. Pharmacological inhibition of P-glycoprotein transports enhances the distribution of HIV-1 protease inhibitors into brain and testes. *Drug Metab.Dispos.* 28: 655-660.
- Córdoba-Díaz, D.,Córdoba-Díaz, M.,Awad, S.and Córdoba-Borrego, M. 2001. Efect of pharmacotechnical design on in vitro interaction of ketoconazole tablet with nonsystemic antacid. *International Journal of Pharmaceutics.* 226: 61-68.
- Cuce, L.C., Wroclawski, E.L. and Sampaio, S.A.P.1980. Treatment of paracoccidioidomycosis, candidosis, chromomycosis,lobomycosis, and mycetoma with non-systemic antacid. *International Journal of Pharmaceutics.*226: 61-68.
- Daneshmend, T.K. 1990. Diseases and drugs but not food decrease ketoconazole bioavailability. *Br J Clin Pharmac.* 29 : 783-4.
- Daneshmend, T.K., Mason ,A.R., Warnock, D.W., *et al.* .1986. Influence of formulation on ketoconazole pharmacokinetics in man: comparison of standard tablet versus capsule containing citric acid. *J Anti Chem.* 18 :289-91.
- Daneshmend, T.K., Warnock.D.W., Ene, M.D., *et al.*1983. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetic in man. *Antimicrob Agents Chemother.* 226: 61-68.
- Daneshmend, T.K., Warnock.D.W., Ene, M.D., *et al.*1984. Influence of food on the pharmacokinetics of ketoconazole. *Antimicrob Agents Chemother.*

25(1):1-3.

Degreef, H., Van De Kerckhove, M., Gevers, D., et al. 1981. Ketoconazole (R 41 400) in the treatment of dermatophyte infections. *Intl.J.Dermatol.* 20: 662-669.

Dollery, C. 1999. Itraconazole, Ketoconazole, Quinine. In: *Therapeutic Drugs. 2nd*. vol 2, pp.12 -126, K13-17, London: Hardout brace company limited.

Dominguez, J., Kompatzki, A. And Norambuena, R. 2003. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. *Transplantation Proceedings.* 35: 2522-2523.

Dow, G.S., Hudson, T.H., Vahey, M. and Koenig, M.L. 2003. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function *in vitro*. *Malaria J.* 2: 1-14.

Eller, M.G. and Okerholm, R.A. 1991. Pharmacokinetic interaction between terfenadine and ketoconazole (abstract). *Clin. Pharmacol. Ther.* 49: 130.

Fabris, A., Pellanda, M.V., Gardin, C., et al. 1993. Pharmacokinetics of antifungal agents. *Peritoneal Dialysis International* 13(suppl 2): S380-2.

Fauci, A.S., Macher, A.M., Lango, D.L., et al. 1984. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. *Ann. Intern. Med.* 100: 92-106.

Fleishaker, J.C., Pearson, P.G., Wienkers, L.C., *et al.* 1996. Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. *J. Pharmacol. Exp. Ther.* 227(2): 991-998.

Franseen, G., Rouveix, B., Bauchet, J., Verdier, F., Michon, C., Bricaire, F. 1989. Divided-dose kinetics of mefloquine in man. *British Journal of Clinical Pharmacology.* 28 : 179-184.

Fontaine, F., Sousa, G., Burcham, P.C., Duchene, P. And Rahmani, R. 2000. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. *Life Science.* 66(22): 2193-2212.

Foster, S. 1994. Economic prospects for a new antimalarial drug. *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 55 (suppl. 1, 1994), 55 -56.

Galimberti, R., Negroni, R., Iglesia de Elias, M.R., *et al.* 1980. The activity of ketoconazole in the treatment of onychomycosis. *Rev. Infect. Dis.* 2:596-598.

Gascoigne, E.W., Barton, G.J., Michaels, M., *et al.* 1981. The kinetics of ketoconazole in animal and man. *Clin. Res. (Review)* 1: 177-187.

Ghetti, P., Patrone, P. and Tosti, A. 1986. Ketoconazole in the treatment of acne in women (letter). *Arch. Dermatol.* 122: 629.

Ginsburg, C.M., McCracken, G.H. and Olsen, K. 1983. Pharmacology of ketoconazole suspension infants and children. *Antimicrob Agents*

Chemother. 23: 787-789.

Gonzalez, F.J. and Idle, J.R. 1994. Pharmacogenetic phenotyping and genotyping present status and future potential. *Clin. Pharmacokinet.* 26: 59-70.

Graybill, J.R. and Drutz, D.J. 1980. Ketoconazole: A major innovation for treatment of fungal disease. *Ann. Intern. Med.* 93: 921-923.

Graybill, J.R., Galgiani, J.N. Jorgensen, J.H., *et al.* 1983. Ketoconazole therapy for fungal urinary tract infections. *J. Urol.* 129: 68-70.

Greenblatt, D.J., Von Moltke, L.L., Harmatz, J.S., *et al.* 1993. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. *J. Clin. Psychiatry.* 54(suppl 10): 4-11.

Greenblatt, D.J., Von Moltke, L.L., Harmatz, J.S., *et al.* 1995. Interaction of triazolam and ketoconazole (letter). *Lancet.* 345: 191.

Greenblatt, D.J., Von Moltke, L.L., Harmatz, J.S., *et al.* 1998. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. *Clin. Pharmacol. Ther.* 64: 661-671.

Greenblatt, D.J., Wright, C.E., Von Moltke, L.L., *et al.* 1998. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. *Clin. Pharmacol. Ther.* 64: 237-247.

Greiner, B., Eichelbaum, M., Fritz, P., *et al.* 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. *J. Clin. Invest.*

104: 147-153.

Guengerich, F.P., Brian, W.R., Iwasaki, M., *et al.* 1991. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 3A4. *J.Med Chem.* 34:1838-1844.

Goldsmith, R.S.2000. Antiprotozoal Drug. In B.G. Katzung (ed), Basic and Clinical Pharmacology (8th ed), pp. 723-747. New York: McGraw-Hill.

Halpert, J.R.1995. Structural basis of selective cytochrome P450 inhibition. *Annual Review of Pharmacology and Toxicology.* 35: 29-53.

Harinasuta, T., Bunnag, D., Wernsdorfer, W.H. 1983. A phase 2 clinical trial of mefloquine in patient with chloroquine-resistant falciparum malaria in Thailand. *Bulletin of the World Health Organization.* 61 : 299-305.

Hawkin, S.S., Greony, D.W. and Alford,R.H. 1981. Progressive disseminated histoplasmosis: favorable response to ketoconazole. *Ann.Intern.Med.* 95: 446-449.

Hay, R.J., and Clayton,Y.M. 1982. Treatment of chronic dermatophyte infections. The use of ketoconazole in griseofuvin treatment failures. *Clin.Exper.Dermatol.*7: 611-617.

Heel, R.C., Brogden, R.N., Carmine, A. *et al.* 1982. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. *Drugs.* 23: 1-36.

- Heinig,R., Adelman, H.G. and Ahr, G. 1999. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. *Eur. J. Clin. Pharmacol.* 55: 57-60.
- Herman, B.D., Fleishaker, J.C. and Brow, M.T.1999.Ketoconazole inhibits the clearance of the enantiomers of antidepressant reboxetine in humans. *Clin.Pharmacol.Ther.* 66(4): 374-379.
- Hesselink, D.A., Schaik,R.H.N., Heiden, I.P., *et al.* 2003. Genetic polymorphisms of the *CYP3A4,CYP3A5*, and *MDR-1* genes and pharmacokinetics of the calcineurin inhibitors cyclosporin and tacrolimus. *Clin. Pharmacol. Ther.*74: 245-254.
- Honing, P.K., Wortham, D.C., Hill, R. *et al.* 1993. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. *J. Clin. Pharmacol.*33: 1201-1206.
- Hoppu, K., Tapanainen, P., Tikanoja, T., *et al.* 1991. Accidental astemizole overdose in young children.*Lancet.* 338: 538-539.
- Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. *J.Biol.Chem.*268: 14991-14997.
- Jalava, K-M., Olkkola, K.T., Neuvonen, P.J. 1997. Itraconazole greatly increases plasma concentrations and effects of felodipine. *Clin Pharmacol Ther.*61: 410-415.

- Josefsson, M., Zackrisson, A.L. and Ahlner, J. 1996. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. *Eur. J.Clin. Pharmacol.* 51:189-193.
- Kang, J., Chen, X.L., Wang, L. and Rampe, D. 2001. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. *The Journal of Pharmacology and Experimental Therapeutics.* 299: 290-296.
- Karbwang J, Back D.J, Bunnag D. and Breckenridge A.M. 1988a.
A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. *European Journal of Clinical Pharmacology.* 35: 677-680.
- Karbwang, J. 1988b. Effect of Oral Contraceptive Steroids on the Clinical course of Malaria Infection and on the Pharmacokinetics of Mefloquine in Thai woman. *Bulletin of the World Health Organization.* 66: 763-767.
- Karbwang, J., Na-Bangchang, K., Thanavibul, A., Back D.J., Bunnag, D. 1992. Pharmacokinetics of mefloquine in the presence of phenytoin. *European Journal of Clinical Pharmacology.* 20 : 323-326.
- Karbwang, J. and White, N.J. 1990. Clinical Pharmacokinetics of mefloquine. *Clinical Pharmacokinetics.* 19: 264-279.
- Kaukonen, K-M, Olkkola, K.T., Neuvonen, P.J. 1997. Itraconazole increases plasma concentrations of quinidine. *Clin Pharmacol Ther.* 62: 510-517.

- Kelly, S. L., Quail, M. A., Rowe, J. & Kelly, D. E. 1992. Sterol 14a-demethylase: target for azole antifungals. In *New Approaches for Antifungal Drugs* (Fernandes, P. B., ed.), pp. 155-187, Birkhauser, Boston, MA.
- Khosla, S., Wolfson, J.S. Demerjian, Z. *et al.* 1989. Adrenal crisis in the setting of high-dose ketoconazole therapy. *Arch.Intern.Med.* 149: 802-804.
- Khaliq, Y., Gallicano, K., Venance, S., *et al.* 2000. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patient infected with human immunodeficiency virus. *Clin. Pharmacol. Ther.* 68: 637-646.
- Kim, R.B., Fromm, M.F., Wandel, C., *et al.* 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitor. *J.Clin.Invest.* 101: 289-294.
- Kivisto, K.T, Lamberg, T.S., Kantola, T., Neuvonen, P.J. 1997. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. *Clin Pharmacol Ther.* 62:348-354.
- Krishna, S. and White, N.J. 1996. Pharmacokinetics of quinine, chloroquine and amodiaquine : Clinical implications. *Clinical Pharmacokinetics.* 30: 263-299.
- Koch, H. 1983. Ketoconazole. *Pharm.Int.* 4: 151-152.
- Kosten, T.R., Oliveto, A., Sevarino, K.A., *et al.* 2002. Ketoconazole increases

cocaine and opioid use in methadone maintained patients. *Drug and Alcohol Dependence*. 66: 173-180.

Kotegawa, T., Laurijssens, B.E., Von Moltke, L.L., *et al.* 2002. In vitro, Pharmacodynamic interactions of ketoconazole and midazolam in the rat. *The Journal of Pharmacology and Experimental Therapeutics*. 302(3): 1228-1237.

Kovacs, G.T., Westcott, M. and Rusden, J.1990. A prospective study to assess the efficacy of ketoconazole in the treatment of recurrent vaginal candidiasis. *Med.J.Aust.*153: 328-330.

Laurberg, G.1982. Ketoconazole in trichophyton rubrum. *Acta Dermatovener.* 62: 273-274.

Legendre, R. And Steltz, M. 1980. A multi-center, double-blind comparison of ketoconazole and griseofuvin in the treatment of infections due to dermatophytes.*Rev.Infet. Dis.*2: 586-591.

Lin, J. L. and Lu, A.Y.H. 1998. Inhibition and induction of cytochrome P450 and the clinical implications.*Clin.Pharmacokinet.*35: 361-390.

Lin, J.H. 2003. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Advanced Drug Delivery Reviews*.55: 53-81.

Looareesuwan, S., Chongsuphajaisiddhi, T. 1994. Malaria. In: *Clinical Tropical Medicine I*. 1st ed, Looareesuwan et al eds. Bangkok, Medical Media, pp. 1-61.

- Lyman, C.A. and Walsh, T.J. 1992. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic application. *Drug.* 44(1): 18-34.
- Maksymink, A.W., Levine, H.B. and Bodey, G.P. 1982. Pharmacokinetics of ketoconazole in patients with neoplastic diseases. *Antimicrob Agents Chemother.* 22: 43-46.
- Mandell, G.L., Douglas, R.G. and Bennett, J.E. (eds). 1990. *Principle and Practice of Infectious Diseases*, 3rd ed. Churchill Livingstone, New York, NY.
- Mansor, S.M., Naravatnam, V., Mohamad, M., *et al.* 1989. Single dose kinetic study of the triple combination mefloquine-sulfadoxine-pyrimethamine (Fasimef) in healthy male volunteers. *Br. J. Clin. Pharmacol.* 27: 381-386.
- Martinez-Jorda, R., Rodriguez-Sasiain, J.M. *et al.* 1990. Serum binding of ketoconazole in health and disease. *Int. J. Clin. Pharm. Res.* 10: 271-276.
- Mathews, D.R., McNutt, B., Okerholm, R. *et al.* 1991. Torades de pointes occurring in association with terfenadine use (letter). *JAMA.* 266: 2375-2376.
- McGrawth, J. and Murphy, G.M. 1991. The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. *Drugs.* 41(2): 178-184.
- Meyer, K.C., McManus, E.J. and Maki, D.G. 1993. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome.

*N.Eng.J.Med.*329: 1231-1236.

Mirghani, R.A., Hellgren, U., Westerberg, PA., Ericsson, O., Bertilsson, L., Gustafsson, L.L. 1999. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. *Clin Pharmacol Ther.* 66(5): 454-460.

Mirghani, R.A., Hellgren, U., Bertilsson, L., *et al.* 2003. Metabolism and elimination of quinine in healthy volunteers. *E. J. Clin. Pharmacol.* 59 (5-6): 423-427.

Mobacken, H. and Moberg, S. 1986. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis: a prospective 3 years trial. *Dermatological.* 173: 229-236.

Na-Bangchang, K., Karbwang, J. and Back, D.J. 1992. Mefloquine metabolism by human liver microsomes : effect of other antimalarial drugs. *Biochemical Pharmacology.* 43: 1957-1961.

Na-Bangchang, K., Karbwang, J., Bunnag, D., Harinasuta, T. 1991. The effect of etroclopramide on mefloquine pharmacokinetics. *British Journal of Clinical Pharmacology.* 32: 640-641.

Na-Bangchang, K., Congpuong, K., Sirichaisinthop, J., Suprakorb, K., Karbwang, J. 1997. Compliance with a 2 day course of artemether-mefloquine in an area of highly multi-drug resistant *Plasmodium falciparum* malaria. *Br J Clin Pharmacol* 43: 639-642.

Na-Bangchang, K., Molunto, P., Banmairuroi, V., Thanavibul, A., Karbwang, J.

1995. Pharmacokinetics of mefloquine when given as a single and two divided dose regimens. *Int J Clin Pharm Res* .15: 215-220.

Negrone, R., Robles, A.M., Arechavala, A., *et al.*1980. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. *Rev. Infect. Dis.*2: 643-649.

Neubaure, M.A. and Bodensteiner, D.C.1992. Disseminated histoplasmosis in patients with AIDS. *South.Med.J.*85: 1166-1170.

Neuvonen, P.J. and Suhonen, R.1995. Itraconazole interacts with felodipine. *J. Am. Acad.Dermatol.*33: 134-135.

Obasi, O.E. and Ozoh, G.1988. Ketoconazole treatment of dermatomycoses in Kaduna, Nigeria. *Curr.Ther.Res.*43: 931-941.

Oftebro, H., Jensen, J., Mowinckel, P., *et al.* 1994. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. *J.Clin.Endocrinol.Metab.* 78(4): 973-977.

Olkola, K.T, Backman, J.T., Neuvonen, P.J.1994. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther.* 55: 481-485.

Palmer, K.J., Holliday, S.M., Brogden, R.N.1993. Mefloquine A Review of its Antimalarial Activity. *Pharmacokinetic Properties and Therapeutic Efficacy Drug.* 45: 430-475.

- Palkama, V.J., Ahonen, J., Neuvonen, P.J., *et al.* 1999. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. *Clin.Pharmacol.Ther.*55: 481-485.
- Pappas, P.G., Pottage, J.C., Powderly, W.G., *et al.* 1992. Blastomycosis in patients with the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 116: 847-853.
- Pershing, L.K., Corlett, J. and Jorgensen, C. 1994. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human statum cornu. *Antimicrob Agents Chemother.* 38(1): 90-95.
- Polk, R.E., Crouch, M.A., Israel, D.S., *et al.* 1999. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. *Pharmacotherapy.* 19: 1378-1384.
- Product Information. 1999. Abelcet®, amphotericin B lipid complex. The Liposome Company, Inc., Princeton, NJ.
- Product Information. 2000. Agenerase®, amprenavir. Glaxo Wellcome Inc., Research Triangle Park, NC.
- Product Information. 1996. Albenzal®, asbendazole tablet. Smithkline Beecham Pharmaceuticals, Philadelphia, PA.
- Product Information. 1995. Nizoral® 2% Shampoo. Janssen Pharmaceutica, Titusville, NJ.
- Product Information. 2000. Nizoral® 2% Shampoo. Janssen Pharmaceutica,

Titusville, NJ,(PI revised 8/1997)reviewed 5/2000.

Product Information.2000. Nizoral® 2% Shampoo.Janssen Pharmaceutica,
Titusville, NJ,(PI revised 7/1998)reviewed 2000.

Product Information.1998. Nizoral®, ketoconazole.Janssen Pharmaceutica,
Titusville, NJ.

Product Information.1996. Nizoral®, ketoconazole.Janssen Pharmaceutica,
Titusville, NJ.

Product Information.2001. Sporanox®,injection.Janssen Pharmaceutica, Titusville,
NJ,(PI revised 04/2001) reviewed 05/2001.

Product Information.1997. Versed®, midazolam.Roche Laboratories Inc.,
Titusville, NJ.

Product Information.1997. Xanax®, alprazolam. Pharmacia & Upjohn
Company,Kalamazoo,MI.

Renton, K.W. 1986. Factors affecting drug biotransformation. Clin.Biochem. 19:
72-75

Restrepo, A., Stevens, D.A., Gomez,I., *et al.*1980. Ketoconazole: anew drug
for the treatment of paracoccidioidomycosis.*Rev.Infect.Dis.*2: 633-642.

Ridtitid, W., Wongnawa, M., Mahatthanatrakul, W., Chaipol, P. and
Sunbhanich, M. 2000. Effect of rifampin on plasma concentrations of

mefloquine in healthy volunteers. *J Pharmacol.*52: 1265-1269.

Ridtitid, W., Wongnawa, M., Mahatthanatrakul, W., Phaipenkong, P.,
Suvarnarak, T. and Sunbhanich, M. 2000. Effect of ketoconazole and
itraconazole on plasma concentrations of quinine in normal healthy
volunteers. *Thai J Pharmacol.* 23: 101-108.

Robertson, M.H., Hanifin, J.M. and Parker, F.1980. Oral therapy with
ketoconazole for dermatophyte infections unresponsive to griseofuvin.
*Rev.Infect.Dis.*2: 578-581.

Robertson, M.H.,Rich, P., Parker, F., *et al.*1982. Ketoconazole in griseofuvin-
resistant dermatophytosis. *J.Am.Acad.Dermatol.*6:224-229.

Rowland, M. and Tozer, T.N.1995. *Clinical Pharmacokinetics: Concepts and
Applications* (3rd Edn ed.), Williams and Wilkins, Baltimore.

Serody, J.S., Mill, M.R.,Detterbeck, F.C., *et al.*1993. Blastomycosis in
transplant recipients:report of case and review. *Clin.Infect.Dis.*16: 54-58.

Sikka, S. C., Swerdloff, R. S. and Rajfer, J. 1985. In vitro inhibition of
testosterone biosynthesis by ketoconazole. *Endocrinology.* 116,1920-
1925.

Silveira, L.H., Cuellar, M.L., Citera, G., *et al.*1993. Candida arthritis. *Rheum.
Dis Clin.North.Am.*19: 427-437.

Silveman, J.A.2000. P-glycoprotein. In R.H. Levy, *Metabolic Drug Interactions.*

pp.135-144.Philadelphia: A Wolters Kluwer.

Simpson, J.A., Price, R., Kuile, F., *et al.*1999. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. *Clin. Pharmacol. Ther.* 66: 472-484.

Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F.P.1994. Interindividual variations in human liver microsomes P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. *J Pharmacol Exp Ther.* 270:414-423.

Shuster, S. 1984. The etiology of dandruff and mode of action of therapeutic agents. *Br. J. Dermatol.* 111: 235-242.

Smith, A.G. 1984. Potentiation of oral anticoagulants by ketoconazole. *Br.Med.J.* 288: 188-189.

Snook, J., Boothman, B.D., Watkins, J. *et al.*1988. Torsade de point ventricular tachycardia associated with astemizole overdose. *Br.J.Clin.Pract.* 42: 257-259.

Sobel, J.D.1986. Recurrent vulvovaginal candidiasis:a prospective study of the efficacy of maintenance ketoconazole therapy. *N.Engl.J.Med.*315:1455-1458.

Sobh, M., El-Agroudy, A., Moustafa, F., *et al.*1995. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a

prospective randomized study. *Am.J.Nephrol.*15: 493-499.

- Soltero, L., Carbajal, H., Rodriguez-Montalvo, C. And Valdes, A. 2003. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. *Transplantation Proceedings.* 35: 1319-1321.
- Sugar, A.M., Alsip, S.G., Galgiani, J.N., et al. 1987. Pharmacology and toxicity of high dose of ketoconazole. *Antimicrob. Agents Chemother.*31: 1874-1878.
- Sugar, A.M., Stern, J.J. and Dupont, B. 1990. Overview: treatment of cryptococcal meningitis. *Rev. Infect. Dis.*12(Suppl 3): S338-S348.
- Sunbhanich, M., Ridditid, W., Wongnawa, M., Akesiripong, S., Chamnongchob, P. 1997. Effect of Cimetidine on an oral single-dose mefloquine pharmacokinetics in humans. *Asia Pac J Pharmacol.* 12: 51-55.
- Suzuki, S., Kurata, N., Nishimura, Y., Yasuhara, H., Satoh, T. 2000. Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. *Eur. J. Drug Metab. Pharmacokinet.* 25: 21-126.
- Tanaka, E. 1998. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. *J Clin Pharm Ther.* 23: 403-416.
- Taylor, S., Gupta, A., Walker, S. et al. 1996. Peripheral edema due to nifedipine-itraconazole interaction: a case report. *Arch. Dermatol.*132: 350-352.

- Talbot, M.D. and Spencer, R.C. 1983. Oral ketoconazole in the treatment of vaginal candidiasis. *Cur.r Ther. Res.* 34:746-749.
- Thomas, R.K., Alison, O., Kevin, A.S., *et al.* 2002. Ketoconazole increases cocaine and opioid use in metadone maintained patients. *Drug and Alcohol Dependence.* 66: 173-180.
- Thomas, K., Rob, L.H., Jansen, M.D., *et al.* 2001. Modulation of cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. *Clin. Pharmacol. Ther.* 70: 132-141.
- Tsunoda, S. M., Velez, R. L., Von Moltke, L. L., Greenblatt, D. J. 1999. Differentiation of intestinal and hepatic cytochrome P4503A activity with use of midazolam as an in vivo probe: effect of ketoconazole. *Clin Pharmacol Ther.* 66: 461-471.
- Una, C.C. and Marilyn, E.C. 2001. Effect of ketoconazole on the acquisition of cocaine self-administration under different feeding conditions in rats. *Psychopharmacology.* 154: 311-318.
- Van Der Meer, J.W.M., Kening, J.J., Scheijrond, H.W., Heykants, J., Van Cutsem, J. *et al.* 1980. Influence of gastric acidity on the bioavailability of ketoconazole. *J. Antimicrob. Chemother.* 6: 522-524.
- Van tyle, J.H. 1984. Ketoconazole, mechanism of action spectrum of activity pharmacokinetics, drug interaction, adverse reaction and therapeutic use. *Pharmacotherapy.* 4: 343-373.

- Varhe, A., Olkkola, K.T., Neuvonen, P.J. 1994. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* .56:601-607.
- Venkatakrishnan, K., Von Moltke, L.L., Greenblatt, D.J. 2000. Effects of the antifungal agents on oxidative drug metabolism. *Pharmacokinetic* 38(2): 111-180.
- Vidal-Puig, A.J., Munoz-Torres, M., Jodar-Gimeno, E., *et al.* 1994. Ketoconazole therapy: hormonal and clinical effect in non-tumoral hyperandrogenism. *Eur.J.Endocrinol.*130: 333-338.
- Villikka, K., Kivisto, K.T., Backman, J.T., *et al.* 1997. Triazolam is ineffective in patients taking rifampin. *Clin. Pharmacol. Ther.*61: 8-14.
- Von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M. *et al.* 1994. Inhibitor of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. *Br.J.Clin.Pharmacol.*38:23-31.
- Von Moltke, L.L., Durol, A.L.B., Duan, S.X. and Greenblatt, D.J. 2000. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. *Eur.J.Clin.Pharmacol.*56: 259-261.
- Wang, E., Lew, K. Casciano, C.N., Clement, R.P. and Johnson, W.W. 2002. Interaction of common azole antifungals with P-glycoprotein. *Antimicrobial Agents and Chemotherapy.* 46(1): 160-165.

- Welsh, O. And Rodriguez, M. 1980. Treatment of dermatomycoses with ketoconazole. *Rev. Infect.Dis.*2: 582-585.
- Wernsdorfer, W.H. and Karbwang, J. 2001. Introduction to clinical pharmacology. *Fundamental Clinical Pharmacokinetics*: 1-4. Faculty of Allied Health Sciences.
- Wichmann, O., Betschart, T., Löscher, T., *et al.* 2003. Prophylaxis failure due to probable mefloquine resistance in *P.falciparum* from Tanzania. *Acta. Tropica.* 86: 63-65.
- Wildt, S.N., Kearns, G.L., Leeder, J.S. and Anker, J.N. 1999. Cytochrome P450 3A Ontogeny and Drug Disposition. *Clin. Pharmacokinetics.*37: 485-505.
- Winqvist, E.W. Laskey, J., Crump, M., *et al.* 1995. Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. *J.Clin. Oncol.*13(1):157—1164.
- White, N.J. 1988. Drug treatment and prevention of malaria. *Eur J Clin Pharmacol.* 34: 1-14.
- Zhang, Y. and Benet, L.Z. 2001. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. *Clin. Pharmacol.* 40(3): 159-168.

